Jurnal Internasional Tingkat tinggi remisi lengkap yang tahan lama pada limfoma folikel setelah imunoterapi sel CAR-T CD19
“data-icon-position-position =” “data-hide-link-title =” 0 “>
Abstract  Patients with follicular lymphoma (FL) with initial recurrence after initial chemoimmunotherapy, refractory disease, or histological transformation (tFL) limit free development and overall survival. We report the efficacy and long-term follow-up of 21 patients with FL (n = 8) and refractory (R = R) recurrence and tFL (n = 13) treated in phase 1/2 of clinical trials followed by lymphocamphine and fludarabine depletion. by infusion of 2 × 10 6 CD19 is directed towards chimeric receptor modified T (CAR-T) cells per kilogram. The complete remission rate (CR) by the Lugano criteria was 88% and 46% for patients with FL and tFL, respectively. All patients with FL who achieved CR remained in remission at a median follow-up of 24 months. The median duration of response for patients with tFL was 10.2 months at a median follow-up of 38 months. Cytokine release syndromes occur in 50% and 39%, and neurotoxicity in 50% and 23% of patients with FL and tFL, respectively, without severe side effects (grade ≥3). No significant differences in CAR-T in vivo expansion / persistence cells were observed between FL and tFL patients. CAR-T CD19 cell immunotherapy is very effective in adults with clinically aggressive FL R / R with or without transformation, with long-lasting remission in most FL patients. This trial was registered in clinicaltrials.gov as # NCT01865617 .
- Submitted 2 April 2019.
- Received 22 May 2019.
- ] 2019 by The American Society of Hematology